Baricitinib in the treatment of SARS-CoV-2 infection
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia - 33(2020), 4 vom: 16. Aug., Seite 294-295 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Baricitinib en el tratamiento de infección por SARS-CoV-2 |
|---|
| Beteiligte Personen: |
Gutiérrez-Lorenzo, M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Azetidines |
|---|
| Anmerkungen: |
Date Completed 23.07.2020 Date Revised 11.11.2023 published: Print-Electronic CommentOn: J Infect. 2020 Apr 23;:null. - PMID 32333918 Citation Status MEDLINE |
|---|
| doi: |
10.37201/req/047.2020 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311620191 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311620191 | ||
| 003 | DE-627 | ||
| 005 | 20231225142636.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.37201/req/047.2020 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1038.xml |
| 035 | |a (DE-627)NLM311620191 | ||
| 035 | |a (NLM)32583654 | ||
| 035 | |a (PII)gutierrez25jun2020 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Gutiérrez-Lorenzo, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Baricitinib in the treatment of SARS-CoV-2 infection |
| 246 | 3 | 3 | |a Baricitinib en el tratamiento de infección por SARS-CoV-2 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.07.2020 | ||
| 500 | |a Date Revised 11.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: J Infect. 2020 Apr 23;:null. - PMID 32333918 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a Baricitinib | |
| 650 | 4 | |a SARS-COV-2 | |
| 650 | 4 | |a hospital | |
| 650 | 4 | |a infection | |
| 650 | 4 | |a treatment | |
| 650 | 7 | |a Azetidines |2 NLM | |
| 650 | 7 | |a Purines |2 NLM | |
| 650 | 7 | |a Pyrazoles |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 650 | 7 | |a baricitinib |2 NLM | |
| 650 | 7 | |a ISP4442I3Y |2 NLM | |
| 700 | 1 | |a Cuadros-Martínez, C M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia |d 1997 |g 33(2020), 4 vom: 16. Aug., Seite 294-295 |w (DE-627)NLM090649028 |x 1988-9518 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2020 |g number:4 |g day:16 |g month:08 |g pages:294-295 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.37201/req/047.2020 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2020 |e 4 |b 16 |c 08 |h 294-295 | ||